TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryThe landscape of birth control has traditionally placed the responsibility on women, but this dynamic is changing. Recent clinical trial recruitment efforts reveal a significant willingness among men to participate in male contraceptive studies, reflecting evolving societal attitudes and the urgent need for new contraceptive methods.
TCB TeamFeb 2, 2026
Regulatory & PolicyRecent regulatory developments have put Regenxbio's gene therapy programs for rare diseases under significant scrutiny. This article examines the implications of FDA clinical holds, potential safety concerns, and the broader context of gene therapy regulation in rare disease treatment.
TCB TeamFeb 1, 2026
Regulatory & PolicyShared decision-making involves collaboration between clinicians and patients to make healthcare decisions that align with patient values and preferences. This approach fosters trust and improves treatment adherence, especially in nuanced areas such as prostate cancer screening and vaccine choices.
TCB TeamJan 31, 2026
Regulatory & PolicyOn January 29, 2026, the White House unveiled a fresh, ambitious effort to streamline the country’s approach to addiction. While the rhetoric marks a strong commitment to tackling drug and alcohol misuse, key specifics needed to evaluate the initiative’s potential impact remain unclear. This article explores the context, potential implications, and challenges of this new policy approach.
TCB TeamJan 30, 2026
Biotech InnovationRecent advancements in genetic research have deepened our understanding of human longevity. This article explores the findings of a pivotal study that redefines the impact of inherited genes on lifespan and discusses implications for aging research and therapeutic strategies.
TCB TeamJan 29, 2026
Biotech InnovationPhase 2 data reveal Roche's investigational GLP-1 and GIP agonist achieved a 22.5% placebo-adjusted weight loss at 48 weeks. This efficacy supports the advancement to pivotal Phase 3 trials, marking a critical step in the development of new obesity treatment options amid a highly competitive market.
TCB TeamJan 28, 2026
Regulatory & PolicyThe recent announcement by the Trump administration introduces 15 additional drugs into the Medicare price negotiation process. This includes, for the first time, treatments administered in doctors' offices, marking a significant expansion in the government's approach to controlling drug spending within Medicare. This policy development could have wide-reaching implications for patients, providers, and pharmaceutical companies.
TCB TeamJan 28, 2026
Regulatory & PolicyRecent data indicate a troubling surge in syphilis infections among pregnant populations. This escalation poses serious risks to both maternal and infant health, demanding urgent attention to screening, prevention, and treatment practices in healthcare settings.
TCB TeamJan 27, 2026
Healthcare InvestmentDigital health solutions continue to reshape healthcare delivery, demanding innovative contracting strategies. PHTI’s new playbook outlines how purchasers can effectively apply performance-based contracts to ensure measurable outcomes and accountability in digital health technologies.
TCB TeamJan 27, 2026
Biotech InnovationEndometriosis is a painful condition affecting millions, frequently suffering from diagnostic delays due to complex symptoms and limited testing tools. Several biotech companies are now leveraging advances in diagnostics to develop new tests that promise to simplify and accelerate detection, potentially transforming patient outcomes and quality of life.
TCB TeamJan 26, 2026
Regulatory & PolicyThe Centers for Disease Control and Prevention (CDC) has unexpectedly halted the disbursement of billions in public health infrastructure grants to various states and organizations. This pause threatens to disrupt modernization projects vital for disease surveillance, emergency preparedness, and health data interoperability. The move comes amid growing scrutiny over federal funding allocations and priorities in the aftermath of the pandemic.
TCB TeamJan 24, 2026
Regulatory & PolicyHealth systems nationwide have raised concerns regarding current vulnerabilities in the exchange of electronic health records. This article explores the motivations behind their collective appeal, the risks posed by inadequate data security, and the broader implications for patient care and regulatory reform.
TCB TeamJan 23, 2026